Skip to content


    Exciting News for WebMD Members!

    We've been busy behind the scenes building new message boards for you. You'll have new and easier ways to find messages, connect with others, and share your stories.

    And, this will all be available on your smartphone or other mobile device!

    What Do You Need to Do?

    The message board you're used to will be closing in the coming weeks. While many of your boards will be making the move to our new home, your posts will not. Want to keep a discussion going? Save posts you want to continue (this includes your member profile story), so that you can re-post them in the new message boards.

    Keep an eye here and on your email inbox, we'll be back in touch soon to give you all the information you need!

    Yours in health,
    WebMD Message Boards Management

    News Release re: Capesaris? GTx-758 trials on hold
    az4peaks2 posted:
    [a name="pageTitle" style="color: rgb(0, 0, 102); ">GTx Announces Clinical Hold on Clinical Trials Evaluating Capesaris for First and Second Line Treatments of Advanced Prostate Cancer
    MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb 21, 2012 - GTx, Inc. (Nasdaq: GTXI) announced today that the U.S. Food and Drug Administration (FDA) notified the Company in a telephone call on Friday, February 17, 2012, that the agency has placed a clinical hold on the Company's clinical trials evaluating Capesaris® (GTx-758) for primary (first line) androgen deprivation therapy for advanced prostate cancer and secondary (second line) hormonal treatment. A clinical hold is a notification issued by the FDA to the trial sponsor to delay a clinical trial or suspend an ongoing clinical trial.

    The clinical hold affects GTx's Phase II loading dose finding clinical trial and its Phase IIb maintenance dose finding clinical trial, as well as its Phase II clinical trial in men with castration resistant prostate cancer. The clinical hold, which is effective immediately, follows the Company's reports to the FDA of an increased risk of venous thromboembolic events, or blood clots, in subjects treated with Capesaris at the doses studied (1000 mg and higher) and the Company's request to discuss changes in its clinical development program. GTx has suspended further enrollment into these studies and has notified clinical sites to discontinue treatment of subjects.

    The Company believes there may be a path forward to develop Capesaris at lower doses to treat men with metastatic hormone sensitive prostate cancer or castration resistant prostate cancer. The Company will work with the FDA to determine the appropriate course of action to evaluate Capesaris in these patient populations.

    Helpful Tips

    How to get the most out of your prostate cancer consultationExpert
    Here are a few tips to get the most out of your prostate cancer surgical or radiation oncology consultation: 1. Have extra copies of all ... More
    Was this Helpful?
    5 of 5 found this helpful

    Related Drug Reviews

    • Drug Name User Reviews

    Report Problems With Your Medications to the FDA

    FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

    For more information, visit the Duke Health Prostate Cancer Center